|Bid||110.11 x 800|
|Ask||110.14 x 800|
|Day's range||109.68 - 112.27|
|52-week range||81.66 - 114.46|
|Beta (3Y monthly)||0.62|
|PE ratio (TTM)||33.85|
|Earnings date||18 Feb 2020|
|Forward dividend & yield||2.16 (1.94%)|
|1y target est||121.90|
Medtronic plc (MDT) today announced U.S. Food and Drug Administration (FDA) approval of the IN.PACT™ AV drug-coated balloon (DCB), a paclitaxel-coated balloon indicated for the treatment of failing arteriovenous (AV) access in patients with end-stage renal disease (ESRD) undergoing dialysis. AV fistulae are created and used to enable hemodialysis for patients with ESRD.
Zacks.com featured highlights include: Medtronic Public, Arconic, Nasdaq, Hewlett Packard and Target
Medtronic (MDT) delivered earnings and revenue surprises of 2.34% and 0.38%, respectively, for the quarter ended October 2019. Do the numbers hold clues to what lies ahead for the stock?
Revenue of $7.7 Billion Increased 3.0% Reported and 4.1% Organic GAAP Diluted EPS of $1.01; Non-GAAP Diluted EPS of $1.31 Cash Flow from Operations of $1.9 Billion Grew 61%;.
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
The Medtronic 2019 Integrated Performance Report Shares Progress on Pay Equity, Diversity in Management Roles, Access to Healthcare, Environmental Performance, UN Sustainable.
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic (MDT) presents favorable results from study on leadless pacemaker, indicating potential for improving cardiac functions in patients having blockages.
DUBLIN, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT) today announced results from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study showing that an investigational set of algorithms in the Micra™ Transcatheter Pacing System (TPS) significantly improves synchrony and cardiac function in patients with impaired electrical conduction between the chambers of the heart, called atrioventricular (AV) block. The results from the MARVEL 2 study will be presented Nov. 16 during a Featured Science session at American Heart Association 2019, the AHA Scientific Sessions and were published today in JACC: Clinical Electrophysiology.
DUBLIN and LAS VEGAS, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT) today announced four-year data from the IN.PACT Global study, which reinforce the long-term durability and safety of the IN.PACT™ Admiral™ drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries. Professor Thomas Zeller, M.D., director of the Department of Angiology at Universitaets-Herzzentrum, Freiburg-Bad Krozingen, Germany, presented the new, four-year results from the full clinical cohort of the IN.PACT Global Study. The results are the first four-year, real-world, fully adjudicated DCB data to be presented in a scientific congress.
Medtronic plc (MDT) announced today that it will report financial results for the second quarter of fiscal year 2020 on Tuesday, November 19, 2019. The news release will include summary financial information for the company’s second quarter of fiscal year 2020, which ended on Friday, October 25, 2019. Medtronic will host a webcast at 7:00 a.m. CST to discuss financial results for its second quarter of fiscal year 2020.
Medtronic plc (MDT) today announced Shonin approval from the Ministry of Health, Labour and Welfare (MHLW) and the launch of the Valiant Navion™ thoracic stent graft system in Japan for the minimally invasive repair of thoracic descending aortic aneurysms (TAA) and complicated type B aortic dissections (TBAD). The news marks the third major geographical launch of the Valiant Navion, following FDA and CE Mark approvals in late 2018. The low-profile Valiant Navion system is built to further improve upon the performance of the market-leading Valiant™ Captivia™ thoracic stent graft system, which has treated more than 100,000 patients globally, while also broadening patient applicability.
Medtronic plc (MDT) today announced the U.S. launch of its advanced Patient Programmer technology for Deep Brain Stimulation (DBS) therapy at the Samsung Developers Conference in San Jose, Calif. The new programmer – which received U.S. Food and Drug Administration (FDA) approval on July 3, 2019 – leverages a user-friendly, custom-configured Samsung mobile device which allows patients to manage their therapy more simply and discreetly. To date, more than 150,000 patients have been implanted with Medtronic DBS devices for management of Parkinson’s symptoms and other conditions. “It is important for patients to have access to advanced technology for user-friendly therapy management at home,” says Sandeep Thakkar, D.O., neurologist and movement disorder specialist at Hoag’s Pickup Family Neurosciences Institute.
Medtronic plc (MDT), the global leader in medical technology, today announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for the Medtronic Fully Implantable Left Ventricular Assist Device (LVAD) for patients with advanced heart failure, currently in development. Currently, LVAD systems include an implanted heart pump to increase the amount of blood that circulates through the body. The FDA Breakthrough Device Program is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.
The big shareholder groups in Medtronic plc (NYSE:MDT) have power over the company. Institutions will often hold stock...